AAPL337.00+4.59 (+1.38%) ▲|ABBV264.02+1.51 (+0.58%) ▲|ABT102.23-0.13 (-0.13%) ▼|ACN190.29+0.65 (+0.34%) ▲|ADBE252.67+2.17 (+0.87%) ▲|AMAT417.40+2.02 (+0.49%) ▲|AMD545.09+32.59 (+6.36%) ▲|AMGN379.78+3.43 (+0.91%) ▲|AMT175.58-0.81 (-0.46%) ▼|AMZN251.19+5.23 (+2.13%) ▲|AVGO347.30+7.79 (+2.29%) ▲|AXP311.17-1.26 (-0.40%) ▼|BA197.00-4.96 (-2.46%) ▼|BAC58.18+0.28 (+0.48%) ▲|BKNG170.52-0.88 (-0.51%) ▼|BLK1,053.96+16.72 (+1.61%) ▲|BMY62.84-0.76 (-1.20%) ▼|BNY153.02-0.45 (-0.29%) ▼|BRK-B509.20-10.60 (-2.04%) ▼|C132.70-0.25 (-0.19%) ▼|CAT798.57+15.85 (+2.03%) ▲|CL87.73+0.71 (+0.82%) ▲|CMCSA22.91-0.82 (-3.46%) ▼|COF202.04-1.15 (-0.57%) ▼|COP133.19+0.65 (+0.49%) ▲|COST893.93+0.19 (+0.02%) ▲|CRM242.85-7.25 (-2.90%) ▼|CSCO110.24+2.50 (+2.32%) ▲|CVS90.27-1.45 (-1.58%) ▼|CVX211.57+0.03 (+0.01%) ▲|DE685.63+16.16 (+2.41%) ▲|DHR212.50+4.14 (+1.99%) ▲|DIS105.35-1.64 (-1.53%) ▼|DUK118.54+0.78 (+0.66%) ▲|EMR147.40+1.57 (+1.08%) ▲|FDX305.88+4.16 (+1.38%) ▲|GD355.95-4.05 (-1.13%) ▼|GE313.47+0.57 (+0.18%) ▲|GEV924.93-0.16 (-0.02%) ▼|GILD150.89+3.21 (+2.17%) ▲|GM86.62+2.33 (+2.76%) ▲|GOOG343.68+4.32 (+1.27%) ▲|GOOGL347.33+4.46 (+1.30%) ▲|GS951.47+13.49 (+1.44%) ▲|HD302.51+0.04 (+0.01%) ▲|HON206.49-1.17 (-0.56%) ▼|IBM237.75+0.26 (+0.11%) ▲|INTC108.80+7.75 (+7.67%) ▲|INTU313.13-5.00 (-1.57%) ▼|ISRG383.54+1.25 (+0.33%) ▲|JNJ270.22+2.94 (+1.10%) ▲|JPM349.31+0.39 (+0.11%) ▲|KO88.06+0.19 (+0.22%) ▲|LIN458.48-3.61 (-0.78%) ▼|LLY1,152.44+14.62 (+1.28%) ▲|LMT538.09+0.84 (+0.16%) ▲|LOW194.19+0.09 (+0.05%) ▲|LRCX269.31+0.08 (+0.03%) ▲|MA565.73-2.02 (-0.36%) ▼|MCD248.48-0.08 (-0.03%) ▼|MDLZ62.04-0.32 (-0.51%) ▼|MDT92.77+0.17 (+0.18%) ▲|META682.31+9.00 (+1.34%) ▲|MMM164.71+2.06 (+1.27%) ▲|MO69.70-0.40 (-0.57%) ▼|MRK147.15+2.24 (+1.55%) ▲|MS203.52+1.10 (+0.54%) ▲|MSFT497.75+7.45 (+1.52%) ▲|MU977.50+50.95 (+5.50%) ▲|NEE81.28+0.91 (+1.13%) ▲|NFLX75.31-1.10 (-1.44%) ▼|NKE36.36+0.58 (+1.62%) ▲|NOW138.47-1.35 (-0.97%) ▼|NVDA219.34+5.44 (+2.54%) ▲|ORCL150.59+7.43 (+5.19%) ▲|PEP133.66-0.68 (-0.51%) ▼|PFE27.64+0.18 (+0.66%) ▲|PG147.55+0.53 (+0.36%) ▲|PLTR176.24+1.90 (+1.09%) ▲|PM190.48-1.23 (-0.64%) ▼|QCOM188.71+3.87 (+2.09%) ▲|RTX193.54-3.29 (-1.67%) ▼|SBUX96.67-0.67 (-0.69%) ▼|SCHW104.63-0.53 (-0.50%) ▼|SO86.76+0.53 (+0.61%) ▲|SPG204.47+1.53 (+0.75%) ▲|T25.39-0.47 (-1.82%) ▼|TMO658.32+9.89 (+1.53%) ▲|TMUS166.45-9.81 (-5.57%) ▼|TSLA366.20+8.12 (+2.27%) ▲|TXN258.14-2.53 (-0.97%) ▼|UBER70.87-0.10 (-0.14%) ▼|UNH375.21-0.05 (-0.01%) ▼|UNP282.48+1.56 (+0.56%) ▲|UPS100.17+1.40 (+1.42%) ▲|USB60.25+0.52 (+0.87%) ▲|V369.93-1.00 (-0.27%) ▼|VZ48.33-1.43 (-2.87%) ▼|WFC86.89-0.16 (-0.18%) ▼|WMT106.79-0.71 (-0.66%) ▼|XOM163.27-0.05 (-0.03%) ▼|AAPL337.00+4.59 (+1.38%) ▲|ABBV264.02+1.51 (+0.58%) ▲|ABT102.23-0.13 (-0.13%) ▼|ACN190.29+0.65 (+0.34%) ▲|ADBE252.67+2.17 (+0.87%) ▲|AMAT417.40+2.02 (+0.49%) ▲|AMD545.09+32.59 (+6.36%) ▲|AMGN379.78+3.43 (+0.91%) ▲|AMT175.58-0.81 (-0.46%) ▼|AMZN251.19+5.23 (+2.13%) ▲|AVGO347.30+7.79 (+2.29%) ▲|AXP311.17-1.26 (-0.40%) ▼|BA197.00-4.96 (-2.46%) ▼|BAC58.18+0.28 (+0.48%) ▲|BKNG170.52-0.88 (-0.51%) ▼|BLK1,053.96+16.72 (+1.61%) ▲|BMY62.84-0.76 (-1.20%) ▼|BNY153.02-0.45 (-0.29%) ▼|BRK-B509.20-10.60 (-2.04%) ▼|C132.70-0.25 (-0.19%) ▼|CAT798.57+15.85 (+2.03%) ▲|CL87.73+0.71 (+0.82%) ▲|CMCSA22.91-0.82 (-3.46%) ▼|COF202.04-1.15 (-0.57%) ▼|COP133.19+0.65 (+0.49%) ▲|COST893.93+0.19 (+0.02%) ▲|CRM242.85-7.25 (-2.90%) ▼|CSCO110.24+2.50 (+2.32%) ▲|CVS90.27-1.45 (-1.58%) ▼|CVX211.57+0.03 (+0.01%) ▲|DE685.63+16.16 (+2.41%) ▲|DHR212.50+4.14 (+1.99%) ▲|DIS105.35-1.64 (-1.53%) ▼|DUK118.54+0.78 (+0.66%) ▲|EMR147.40+1.57 (+1.08%) ▲|FDX305.88+4.16 (+1.38%) ▲|GD355.95-4.05 (-1.13%) ▼|GE313.47+0.57 (+0.18%) ▲|GEV924.93-0.16 (-0.02%) ▼|GILD150.89+3.21 (+2.17%) ▲|GM86.62+2.33 (+2.76%) ▲|GOOG343.68+4.32 (+1.27%) ▲|GOOGL347.33+4.46 (+1.30%) ▲|GS951.47+13.49 (+1.44%) ▲|HD302.51+0.04 (+0.01%) ▲|HON206.49-1.17 (-0.56%) ▼|IBM237.75+0.26 (+0.11%) ▲|INTC108.80+7.75 (+7.67%) ▲|INTU313.13-5.00 (-1.57%) ▼|ISRG383.54+1.25 (+0.33%) ▲|JNJ270.22+2.94 (+1.10%) ▲|JPM349.31+0.39 (+0.11%) ▲|KO88.06+0.19 (+0.22%) ▲|LIN458.48-3.61 (-0.78%) ▼|LLY1,152.44+14.62 (+1.28%) ▲|LMT538.09+0.84 (+0.16%) ▲|LOW194.19+0.09 (+0.05%) ▲|LRCX269.31+0.08 (+0.03%) ▲|MA565.73-2.02 (-0.36%) ▼|MCD248.48-0.08 (-0.03%) ▼|MDLZ62.04-0.32 (-0.51%) ▼|MDT92.77+0.17 (+0.18%) ▲|META682.31+9.00 (+1.34%) ▲|MMM164.71+2.06 (+1.27%) ▲|MO69.70-0.40 (-0.57%) ▼|MRK147.15+2.24 (+1.55%) ▲|MS203.52+1.10 (+0.54%) ▲|MSFT497.75+7.45 (+1.52%) ▲|MU977.50+50.95 (+5.50%) ▲|NEE81.28+0.91 (+1.13%) ▲|NFLX75.31-1.10 (-1.44%) ▼|NKE36.36+0.58 (+1.62%) ▲|NOW138.47-1.35 (-0.97%) ▼|NVDA219.34+5.44 (+2.54%) ▲|ORCL150.59+7.43 (+5.19%) ▲|PEP133.66-0.68 (-0.51%) ▼|PFE27.64+0.18 (+0.66%) ▲|PG147.55+0.53 (+0.36%) ▲|PLTR176.24+1.90 (+1.09%) ▲|PM190.48-1.23 (-0.64%) ▼|QCOM188.71+3.87 (+2.09%) ▲|RTX193.54-3.29 (-1.67%) ▼|SBUX96.67-0.67 (-0.69%) ▼|SCHW104.63-0.53 (-0.50%) ▼|SO86.76+0.53 (+0.61%) ▲|SPG204.47+1.53 (+0.75%) ▲|T25.39-0.47 (-1.82%) ▼|TMO658.32+9.89 (+1.53%) ▲|TMUS166.45-9.81 (-5.57%) ▼|TSLA366.20+8.12 (+2.27%) ▲|TXN258.14-2.53 (-0.97%) ▼|UBER70.87-0.10 (-0.14%) ▼|UNH375.21-0.05 (-0.01%) ▼|UNP282.48+1.56 (+0.56%) ▲|UPS100.17+1.40 (+1.42%) ▲|USB60.25+0.52 (+0.87%) ▲|V369.93-1.00 (-0.27%) ▼|VZ48.33-1.43 (-2.87%) ▼|WFC86.89-0.16 (-0.18%) ▼|WMT106.79-0.71 (-0.66%) ▼|XOM163.27-0.05 (-0.03%) ▼|
24.1 C
New York
Friday, September 18, 2026

Tag: partners

newssourceFORcompanyinformationcontent1releasesmarket

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints

Scatec reaches financial close for the 1.1GW solar + 100MW/200MWh BESS Obelisk project

Oslo/Cairo, 15 June 2025: Scatec ASA has reached financial close for the “Obelisk” hybrid solar and battery storage project in Egypt.

Scatec signs PPA for 900MW onshore wind project in Egypt

Oslo/Cairo, 15 June 2025: Scatec ASA, a leading renewable energy solutions provider, has signed a USD-denominated 25-year Power Purchase Agreement (PPA) with the Egyptian Electricity Transmission Company (EETC) for a 900 MW wind project, through its dedicated project company “Shadwan Wind Power SAE” to accelerate Egypt’s transition towards a greener and more sustainable energy mix.

Zilliz Transforms Video Surveillance Industry with AI-Powered Vector Database Solutions

Leading surveillance providers leverage Zilliz Cloud to overcome data overload challenges, enabling real-time threat detection and sub-second video search across enterprise installations. REDWOOD SHORES, Calif.,...

Airbus and McGill University are driving innovation in aerospace with an agreement for experiential learning and research

The initiative will help further propel Quebec and Canadian aerospace on the world stage, thus strengthening Montréal's position as one of the major international...

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

A.I. Saves Ad Industry—Until It Doesn’t.

The Cannes Lions Festival of Creativity, a glorified playground for ad executives who enjoy sipping overpriced cocktails while convincing themselves they're the maestros of...

Guide to Venture Capital & Private Equity Firms 2025: Domestic Firms, Canadian Firms, International Firms, and National & State Associations

Discover the latest 29th edition of the *Guide to Venture Capital & Private Equity Firms*, featuring profiles of 3,000 leading firms worldwide. Updated data includes firm details, partner backgrounds, and current corporate activities. Highlights include a U.S. VC dip, AI investment trends, and fintech shifts. 
Discover the latest 29th edition of the *Guide to Venture Capital & Private Equity Firms*, featuring profiles of 3,000 leading firms worldwide. Updated data includes firm details, partner backgrounds, and current corporate activities. Highlights include a U.S. VC dip, AI investment trends, and fintech shifts.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPartners

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers